BioCryst Pharmaceuticals Inc. has agreed to acquire Astria Therapeutics Inc. in a cash-and-stock transaction valued at approximately $700 million, or $13.00 per Astria share. The deal, approved unanimously by both companies’ boards, is expected to close in Q1 2026 pending regulatory and shareholder approvals. Astria’s lead asset, navenibart, is a long-acting injectable monoclonal antibody in Phase 3 development for hereditary angioedema (HAE) prophylaxis. BioCryst, which markets the oral HAE ...